Incyte Corp. (INCY)
NASDAQ: INCYHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
INCY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $23.36B
- P/E (TTM)
- 58.48
- Forward P/E
- 13.35
- EPS (TTM)
- $1.96
- Dividend yield
- None
- 52-week range
- 89.25 – 132.60
- Day range
- 114.28 – 117.51
- Volume / Avg
- 1.54M / 1.62M
- Beta
- —
- Shares outstanding
- 203.83M
52-week range
INCY stock today
Shares of Incyte (INCY) finished lower on Nov 20 at $114.63, a drop of 1.07% or $1.25 per share, versus the S&P 500's 3.70% decline. Shares are 13.6% below their 52-week high of $132.60, set on Jul 28, 2026 and 28.4% above the 52-week low of $89.25, in the middle of the past year's range. INCY is up 16.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 12.3%.
At 58.5x trailing earnings, Incyte trades in line with the peer-group median of 54.3x. Its forward P/E of 13.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Incyte
Company profileIncyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- CEO
- Mr. William J. Meury
- Headquarters
- Wilmington, DE
- Employees
- 2,844
- Website
- incyte.com
Financial highlights
Full financialsIn fiscal 2025, Incyte generated $5.14 billion in revenue, up 21.2% from fiscal 2024, its 14th consecutive year of revenue growth. Net income was $1.29 billion (+3845.0% year over year), for a net margin of 25.0% versus a median of 10.0% in the prior 5 years. Gross margin was 92.8% (up from 92.6%) and operating margin 29.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B |
| Growth | +21.22% | +14.76% | +8.87% | +13.67% | +11.98% |
| Net income | $1.29B | $32.62M | $597.60M | $340.66M | $948.58M |
| EPS (diluted) | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 |
Analyst forecast
ForecastConsensus (28 analysts)
buy
Avg. price target
$132.17+15.31%
- Strong buy 2
- Buy 11
- Hold 14
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $2.03 vs $-4.27
- Surprise
- +147.54%
INCY news
All INCY news- Incyte Bets on Drug Pipeline and Deals for Growth After Jakafi Exclusivity EndsNasdaq
- Incyte Maps Post-JAKAFI Growth as Key Drug Data and 2027 Launch LoomNasdaq
- Incyte Now #384 Largest Company, Surpassing SBA CommunicationsNasdaqINCY, SBAC
- Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha
- Incyte wins EU nod for Povofortay in hidradenitis suppurativaSeeking Alpha
- INCY Wins European Commission Nod For Skin Disease DrugNasdaqINCY, NVS, COLL
- Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Incyte Wins European Approval For Povofortay In Hidradentis SuppurativaNasdaqINCY, BRK.A
Incyte peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MEDPMedpace Holdings Inc. | 610.54 | -3.70% | $17.08B | vs INCY |
| CRLCharles River Laboratories International Inc. | 314.32 | -4.15% | $15.06B | vs INCY |
| ICLRICON plc | 186.71 | -1.92% | $13.99B | vs INCY |
| IQVIQVIA Holdings Inc. | 245.82 | -1.89% | $40.51B | vs INCY |
| ABSIAbsci Corporation | 7.51 | -7.97% | $1.30B | vs INCY |
| OABIOmniAb Inc. | 4.66 | -7.36% | $679.71M | vs INCY |
| NRCNRC Health | 25.16 | +0.68% | $533.93M | vs INCY |
| MXCTMaxCyte Inc. | 1.37 | +7.03% | $141.45M | vs INCY |
Indexes, lists and sector
Index membership
Incyte stock FAQ
What is Incyte's stock price today?
INCY last traded at $114.63 as of Nov 20, 4:00 PM EST, down 1.07% on the day. Prices are delayed at least 15 minutes.
Does Incyte pay a dividend?
No. Incyte does not currently pay a regular cash dividend.
What is INCY's P/E ratio?
INCY trades at a trailing P/E ratio of 58.48 and a forward P/E of 13.35, compared with a median of 54.3 for its closest peers.
Is Incyte in the S&P 500?
Yes. Incyte (INCY) is a constituent of the S&P 500 index.
Who is Incyte's CEO?
Mr. William J. Meury is the chief executive officer of Incyte Corp., which has about 2,844 employees.
Has INCY ever split its stock?
Yes. The most recent INCY stock split was a 2-for-1 split on Sep 1, 2000, one of 2 splits on record.
What is the INCY 52-week high?
The 52-week high for INCY is $132.60 and the 52-week low is $89.25. The stock is currently 13.6% below its high.